Corteva, Inc. (NYSE:CTVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Corteva, Inc. (NYSE:CTVA) have earned an average recommendation of “Moderate Buy” from the twenty-three ratings firms that are currently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $88.8095.

CTVA has been the topic of a number of research reports. Zacks Research lowered shares of Corteva from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 20th. Morgan Stanley lifted their price target on shares of Corteva from $84.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, May 28th. Citigroup lifted their price target on shares of Corteva from $83.00 to $85.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Berenberg Bank lifted their price target on shares of Corteva from $68.00 to $78.00 and gave the company a “hold” rating in a research note on Thursday, March 26th. Finally, Barclays lifted their price target on shares of Corteva from $84.00 to $91.00 and gave the company an “overweight” rating in a research note on Thursday.

Corteva Stock Down 0.6%

Shares of NYSE CTVA opened at $75.71 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.03 and a current ratio of 1.47. Corteva has a 52-week low of $60.53 and a 52-week high of $85.63. The firm has a 50 day moving average price of $80.19 and a 200 day moving average price of $75.45. The stock has a market cap of $50.63 billion, a P/E ratio of 44.53, a P/E/G ratio of 2.33 and a beta of 0.57.

Corteva (NYSE:CTVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.32. Corteva had a net margin of 6.50% and a return on equity of 9.95%. The firm had revenue of $4.91 billion for the quarter, compared to analyst estimates of $4.64 billion. During the same quarter in the previous year, the firm posted $1.13 earnings per share. The business’s revenue was up 11.0% on a year-over-year basis. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Analysts expect that Corteva will post 3.72 EPS for the current year.

Corteva Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Monday, June 1st were given a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Monday, June 1st. Corteva’s payout ratio is currently 42.35%.

Institutional Trading of Corteva

Institutional investors have recently made changes to their positions in the business. JPL Wealth Management LLC bought a new stake in shares of Corteva in the third quarter worth $25,000. Westfuller Advisors LLC lifted its position in shares of Corteva by 2,764.3% in the first quarter. Westfuller Advisors LLC now owns 401 shares of the company’s stock worth $34,000 after purchasing an additional 387 shares in the last quarter. Garton & Associates Financial Advisors LLC bought a new stake in shares of Corteva in the fourth quarter worth $27,000. Bank of Jackson Hole Trust bought a new stake in shares of Corteva in the fourth quarter worth $28,000. Finally, Redmont Wealth Advisors LLC bought a new stake in shares of Corteva in the third quarter worth $29,000. Institutional investors own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid?2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.